1.Lamivudine: fading into the mists of time.
Clinical and Molecular Hepatology 2017;23(4):314-315
No abstract available.
Lamivudine*
2.Which Method Is Appropriate in Defining the Responsiveness to Lamivudine?.
The Korean Journal of Hepatology 2001;7(1):1-5
No abstract available.
Lamivudine*
3.Lamivudine therapy for type B chronic hepatitis in Korea.
Korean Journal of Medicine 2000;58(4):374-377
No abstract available.
Hepatitis, Chronic*
;
Korea*
;
Lamivudine*
4.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2004;66(2):105-107
No abstract available.
Hepatitis*
;
Interferons*
;
Lamivudine*
5.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2003;65(6):629-630
No abstract availalbe.
Hepatitis*
;
Interferons*
;
Lamivudine*
6.Lamivudine and interferon combination therapy in chronic type B hepatitis.
Korean Journal of Medicine 2004;66(1):1-3
No abstract availalbe.
Hepatitis*
;
Interferons*
;
Lamivudine*
7.Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!.
Gut and Liver 2016;10(6):869-870
No abstract available.
Carcinoma, Hepatocellular*
;
Humans
;
Lamivudine*
8.Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!.
Gut and Liver 2016;10(6):869-870
No abstract available.
Carcinoma, Hepatocellular*
;
Humans
;
Lamivudine*
9.Adefovir dipivoxil for the treatment of lamivudine resistant hepatitis B mutants.
The Korean Journal of Hepatology 2000;6(4):533-534
No abstract availalbe.
Hepatitis B*
;
Hepatitis*
;
Lamivudine*
10.Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?.
Joon Yeul NAM ; Jeong Hoon LEE
Clinical and Molecular Hepatology 2017;23(4):311-313
No abstract available.
Hepatitis B, Chronic*
;
Hepatitis, Chronic*
;
Humans
;
Lamivudine
Result Analysis
Print
Save
E-mail